NCT03004703 (ASSAIL-MI) is a Phase 2 clinical trial of Tocilizumab in Coronary Disease, sponsored by Oslo University Hospital.

Who is sponsoring NCT03004703?

NCT03004703 is sponsored by Oslo University Hospital.

What drugs are being tested in NCT03004703?

Interventions in NCT03004703: Tocilizumab, Sodium chloride 0.9%.

What condition does NCT03004703 study?

NCT03004703 studies Coronary Disease, Myocardial Infarction.

Is NCT03004703 still recruiting?

NCT03004703 is currently completed. Last updated 2 March 2021.

Last reviewed 2021-03-02 · How we verify

NCT03004703: ASSAIL-MI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial

Completed Phase 2 Last updated 2 March 2021

What this trial tests

Phase 2 trial testing Tocilizumab in Coronary Disease in 200 participants. Completed in 10 February 2021.

Timeline

16 March 2017

Primary endpoint
19 February 2020

10 February 2021

Quick facts

Lead sponsor	Oslo University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	200
Start date	16 March 2017
Primary completion	19 February 2020
Estimated completion	10 February 2021
Sites	3 locations across Norway

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →
Sodium chloride 0.9%

Conditions studied

Coronary Disease — all drugs for Coronary Disease →
Myocardial Infarction — all drugs for Myocardial Infarction →

Sponsor

Oslo University Hospital

Who can join

Adults 18 to 80, any sex, with Coronary Disease or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this study is to evaluate the ability of a single administration of tocilizumab to reduce myocardial damage in patients presenting with an acute ST-segment elevation myocardial infarction (STEMI). Secondary objectives are to assess the impact of treatment on: (i) final infarct size, (ii) left ventricular size and function, (iii) inflammation, (iv) extracellular matrix remodeling, (v) lipid parameters, (vi) platelet activation and additional pro- and anti-thrombotic parameters, and (vii) study drug safety and tolerability.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting inflammation in atherosclerosis - from experimental insights to the clinic.
Soehnlein O, Libby P. · · 2021 · cited 723× · PMID 33976384 · DOI 10.1038/s41573-021-00198-1
Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities.
Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT, et al · · 2018 · cited 640× · PMID 29330085 · DOI 10.1016/j.pharmthera.2018.01.001
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.
Broch K, Anstensrud AK, Woxholt S, Sharma K, et al · · 2021 · cited 330× · PMID 33858620 · DOI 10.1016/j.jacc.2021.02.049
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker PM. · · 2019 · cited 205× · PMID 30702995 · DOI 10.1161/circresaha.118.313129
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets.
Chen R, Zhang H, Tang B, Luo Y, et al · · 2024 · cited 169× · PMID 38816371 · DOI 10.1038/s41392-024-01840-1
The Two-Faced Cytokine IL-6 in Host Defense and Diseases.
Narazaki M, Kishimoto T. · · 2018 · cited 139× · PMID 30423923 · DOI 10.3390/ijms19113528
Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes.
Bowker N, Shah RL, Sharp SJ, Luan J, et al · · 2020 · cited 86× · PMID 33096487 · DOI 10.1016/j.ebiom.2020.103062
Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study.
Cai T, Zhang Y, Ho YL, Link N, et al · · 2018 · cited 84× · PMID 30090940 · DOI 10.1001/jamacardio.2018.2287

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other recruiting trials for Coronary Disease

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06736899 — Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07094737 — The Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P) Registry: An Observational Study on Ca · recruiting
NCT06701968 — Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease · NA · recruiting

Other Oslo University Hospital trials

Trials by the same sponsor.

NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03004703 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
Last refreshed: 2 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03004703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing